Rituximab in pemphigus: Road covered and challenges ahead

Vinay, Keshavamurthy; Dogra, Sunil

doi:10.4103/idoj.idoj_290_18

Cited by 8 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab (RTX) is a chimeric murine/human anti‐CD20 monoclonal antibody known as a potential drug for the treatment of pemphigus vulgaris. It is administrated via intravenous infusion 1 . Here we present a case of a 48‐year‐old patient affected with pemphigus vulgaris and developed psoriatic plaques on her scalp, trunk, and extremities 4 months after the second course of RTX.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rituximab‐induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review

Ghadirzade Arani,

Moslemi Haghighi,

Nasiri

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageRituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab‐related cutaneous complications will help them in detection and management.AbstractRituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B‐lymphocytes surface. Although it is used as promising treatment for pemphigus, nowadays it is also a new therapy for other autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, and others like non‐Hodgkin's lymphoma. Although there is increasing evidence regarding the safety and effectiveness of rituximab in these diseases, many cutaneous adverse effects have been reported. Here, we describe a 48‐years‐old patient affected with pemphigus vulgaris who developed psoriatic lesions on her on scalp, trunk, and extremities, 4 months after the second course of rituximab.

show abstract

Section: Introductionmentioning

confidence: 99%

“…It is administrated via intravenous infusion. 1 Here we present a case of a 48-year-old patient affected with pemphigus vulgaris and developed psoriatic plaques on her scalp, trunk, and extremities 4 months after the second course of RTX.…”

Section: Introductionmentioning

confidence: 99%

Rituximab‐induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review

Ghadirzade Arani,

Moslemi Haghighi,

Nasiri

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Rituximab (MabThera, Rituxan) is a chimeric murine/human anti-CD20 monoclonal antibody known as a potential drug for treatment of pemphigus vulgaris. It is administrated via intravenous infusion (1). Here we present a case of a 48-years-old patient affected with pemphigus vulgaris and developed psoriatic plaques on her scalp, trunk and arms four months after the second course of rituximab.…”

Section: Introductionmentioning

confidence: 99%